TNFRSF8 and anaplastic large cell lymphoma: By delivering its microtubule disrupting payload MMAE directly to CD30+ cancer cells, BV, meanwhile, an established standard in first-line or second-line settings in ALCL, has significantly improved treatment efficacy and patient survival while minimizing toxicity, both in combination with chemotherapy or as a single agent.2